Site Information
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma information resources on the Internet that were not listed collectively elsewhere. This was at a time when the only well recognized site was Amanda's Home Page (later renamed Can.Survive).
Growth
The site has grown from a single page to over two hundred and continues to grow.
To see old incarnations of the site, you can use the Internet Archive Wayback Machine:
• Lymphoma Information Network
• Lymphoma Resource Pages
• Still looking for the very old stuff
Today
The site is now celebrating thirteen plus years of helping cancer patients. This does not seem too long but in "Internet Years", this is nearly forever :-). The site main page has currently is up to an average 1000 hits a day (now about 7000 hits/week), 20,000 page views a day and has been accessed from over 60 countries worldwide.
Funding
The owner pays for the site hosting and design costs. The book sales through Amazon generates some referral fees to pay for the site. No "popup ads", "pop under ads" or bad advertising is used. Select ads are being used to better inform patients. Companies providing information / illustrations / counters have links to their sites.
Serious consideration is given for advertising, licensing material or other opportunities. Contact Information.
Contact
On the host page, users with medical questions are encouraged to contact appropriate organizations in their country. Site contacts are directed to the contact page.
Confidentiality
This site does not solicit information from readers. Blog alert subscriber and Healthology newsletter addresses are kept confidential and are never given to anyone or used for other purposes. Any letters or specific web browser information is kept strictly confidential and not disclosed to others. Period. The site follows the HONcode ethics rules from the Health on the Net Foundation. The site was recertified by Health On The Net as recently as April 2008.
Minors
This site does not solicit information from minors, including those under 13. Information on this site may contain medical information relating to biology as it applies to lymphatic cancer. There is no explicit information that targets any group.
Would you like to author material? We can always use a hand!
Would you like to advertise? Contact
Sponsored Links
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...
